Books and Book Chapters

    Mechanistic Network Models in Safety and Toxicity Evaluation of Nutraceuticals

    Gonzalez-Suarez, I.; Martin, F.; Hoeng, J.; Peitsch, M. C.

    Date published
    Feb 19, 2016
    DOI
    10.1016/B978-0-12-802147-7.00022-X
    ISBN
    978-0-12-802147-7
    Published in
    Nutraceuticals: Efficacy, Safety and Toxicity
    Editors
    Gupta, R. C.
    Link to publication
    Topic
    Summary

    Nutraceuticals are food constituents with potential health benefits beyond their nutritional value. In vitro and in vivo studies suggest a protective effect of nutraceuticals against chronic diseases, but the results are not supported fully by clinical evidence. From a toxicological perspective, nutraceuticals are recognized generally as safe at dietary doses; however, they are often consumed at higher doses in the form of nutritional supplements. Exposure to supra-dietary doses of nutraceuticals is of toxicological concern, particularly because some substances may cause genomic changes in target tissues. This chapter describes a systems biology-based approach for the toxicological assessment of nutraceuticals that uses computable mechanistic network models to identify and quantify molecular pathways perturbed upon exposure to high doses of nutraceuticals. This chapter also provides specific examples of how microarray-based transcriptome analyses and high-content screening methods can be applied to evaluate the biological impacts of resveratrol, quercetin, astaxanthin, and epigallocatechin gallate in human cryopreserved hepatocytes and coronary artery endothelial cells.

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.